UniQure has emerged as a compelling gene therapy play over the past 30 days, driven primarily by regulatory de-risking around its lead Huntington's disease program AMT-130. The FDA's decision to accept Phase 1/2 data under an accelerated approval pathway—reversing prior resistance—fundamentally shifted investor sentiment from cautious to constructively bullish. This milestone culminated in a Barclays upgrade to Overweight with a $25-to-$65 price target increase, reflecting restored confidence in the asset's viability. The company capitalized on momentum by successfully executing a $225 million upsized public offering at $45.50 per share, signaling robust institutional demand for early-stage gene therapies addressing neurodegeneration. Concurrently, preliminary Phase I/IIa data for AMT-260 in refractory epilepsy demonstrated tolerability without serious adverse events, building a broader portfolio narrative. Key risks include regulatory execution risk on the BLA pathway and the historically contentious FDA relationship. Looking forward, AMT-130's approval trajectory will dominate near-term valuation, while pipeline expansion in epilepsy could provide meaningful optionality for shareholders.